Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 Inhibitor Canagliflozin with SGLT1 and SGLT2: Inhibition Kinetics, Sidedness of Action, and Transporter-Associated Incorporation Accounting for its Pharmacodynamic and Pharmacokinetic Features ...
Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure | SpringerLink
Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research | Diabetes
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus - ScienceDirect
Top 10 Things Invokana Patients Need To Know... - Childers, Schlueter & Smith, LLC
SGLT2 Inhibitors: A New Class of Diabetes Medications
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease | SpringerLink
SGLT2 inhibitor - Wikipedia
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors - Kidney International
SGLT2 inhibitors
Update on Mx of T 2 DM Emerging
SGLT2 Inhibitors: A Review of Canagliflozin
Canagliflozin (Mechanism of action) | Download Scientific Diagram
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation - American Journal of Kidney Diseases
SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome | American Society of Nephrology
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors - Yakovleva -
Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research | Diabetes
Canagliflozin review – safety and efficacy profile in patients w | DMSO
Mode of action of SGLT2 inhibitors in the kidney. Copied with... | Download Scientific Diagram
Swiss Medical Weekly - Use of SGLT2 inhibitors in cardiovascular diseases: why, when and how?
The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus | Cardiovascular Diabetology | Full Text
Introduction to SGLT2 Inhibition - YouTube
